H.C. Wainwright Downgrades Pacira Pharmaceuticals (PCRX) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- Wall St futures gain as oil slips; telecoms pressured by SpaceX spectrum deal
- Oil rises 4% on revived Middle East worries, Hurricane Isaias supply disruption
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- Telecom stocks tumble on SpaceX spectrum acquisition news
- Chipotle, Starbucks shares volatile after report of potential takeover
Tweet
Share
E-mail
Get Alerts PCRX Hot Sheet
Price: $36.39 --0%
Rating Summary:
9 Buy, 19 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 7 | Down: 10 | New: 20
Rating Summary:
9 Buy, 19 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 7 | Down: 10 | New: 20
Join SI Premium – FREE
H.C. Wainwright analyst Douglas Tsao downgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Buy to Neutral with a price target of $36.50.
For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.
Shares of Pacira Pharmaceuticals closed at $36.39 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Northland Downgrades Astera Labs (ALAB) to Market Perform
- H.C. Wainwright Reiterates Buy Rating on Titan Mining Corp. (TII)
- China Renaissance Downgrades Xiaomi Corp (1810:HK) (XIACF) to Sell
Create E-mail Alert Related Categories
DowngradesRelated Entities
Maynard Um, H.C. Wainwright, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
